<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;ff=20240531141138
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;ff=20240531141138" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 31 May 2024 18:11:39 +0000</lastbuilddate>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>ApoB triumphs once more over LDL-C and non-HDL-C in risk prediction: ready for guidelines?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38819813/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 31:ehae257. doi: 10.1093/eurheartj/ehae257. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38819813/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38819813</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae257>10.1093/eurheartj/ehae257</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38819813</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Martin Bødtker Mortensen</dc:creator>
<dc:date>2024-05-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>ApoB triumphs once more over LDL-C and non-HDL-C in risk prediction: ready for guidelines?</dc:title>
<dc:identifier>pmid:38819813</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae257</dc:identifier>
</item>
<item>
<title>Aerobic, resistance, or combined exercise training and its outcomes on cardiovascular risk profile in overweight or obese adults via a CardioRACE trial: a gap</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38819812/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 31:ehae233. doi: 10.1093/eurheartj/ehae233. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38819812/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38819812</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae233>10.1093/eurheartj/ehae233</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38819812</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:creator>André Pontes-Silva</dc:creator>
<dc:creator>André Luiz Lopes</dc:creator>
<dc:date>2024-05-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Aerobic, resistance, or combined exercise training and its outcomes on cardiovascular risk profile in overweight or obese adults via a CardioRACE trial: a gap</dc:title>
<dc:identifier>pmid:38819812</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae233</dc:identifier>
</item>
<item>
<title>Transfemoral aortic valve implantation and concomitant CAD: the jury is out</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38819811/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 31:ehae141. doi: 10.1093/eurheartj/ehae141. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38819811/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38819811</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae141>10.1093/eurheartj/ehae141</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38819811</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Helene Eltchaninoff</dc:creator>
<dc:creator>Eric Durand</dc:creator>
<dc:date>2024-05-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transfemoral aortic valve implantation and concomitant CAD: the jury is out</dc:title>
<dc:identifier>pmid:38819811</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae141</dc:identifier>
</item>
<item>
<title>Resistance exercise intervention using time for public translation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38819802/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 31:ehae234. doi: 10.1093/eurheartj/ehae234. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38819802/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38819802</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae234>10.1093/eurheartj/ehae234</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38819802</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Duck-Chul Lee</dc:creator>
<dc:creator>Angelique G Brellenthin</dc:creator>
<dc:date>2024-05-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Resistance exercise intervention using time for public translation</dc:title>
<dc:identifier>pmid:38819802</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae234</dc:identifier>
</item>
<item>
<title>Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38819334/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with obesity-related HFpEF, semaglutide reduced NT-proBNP. Participants with higher baseline NT-proBNP had a similar degree of weight loss but experienced larger reductions in HF-related symptoms and physical limitations with semaglutide than those with lower NT-proBNP.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 13:S0735-1097(24)07020-7. doi: 10.1016/j.jacc.2024.04.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The glucagon-like peptide-1 receptor agonist, semaglutide, improved health status and reduced body weight in patients with obesity-related heart failure (HF) with preserved ejection fraction (HFpEF) in the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and HFpEF) program. Whether benefits were due to mechanical unloading or effects on HF pathobiology is uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine if semaglutide 2.4 mg reduced N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with obesity-related HFpEF and compare treatment responses by baseline NT-proBNP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a prespecified secondary analysis of pooled data from 2 double-blind, placebo-controlled, randomized trials (STEP-HFpEF [Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity] and STEP-HFpEF DM [Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes]) testing effects of semaglutide in patients with obesity-related HFpEF. The main outcomes were change in NT-proBNP at 52 weeks and change in the dual primary endpoints of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and body weight by baseline NT-proBNP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, 1,145 patients were randomized. Semaglutide compared with placebo reduced NT-proBNP at 52 weeks (estimated treatment ratio: 0.82; 95% CI: 0.74-0.91; P = 0.0002). Improvements in health status were more pronounced in those with higher vs lower baseline NT-proBNP (estimated difference: tertile 1: 4.5 points, 95% CI: 0.8-8.2; tertile 2: 6.2 points, 95% CI: 2.4-10.0; tertile 3: 11.9 points, 95% CI: 8.1-15.7; P interaction = 0.02; baseline NT-proBNP as a continuous variable: P interaction = 0.004). Reductions in body weight were consistent across baseline NT-proBNP levels (P interaction = 0.21).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with obesity-related HFpEF, semaglutide reduced NT-proBNP. Participants with higher baseline NT-proBNP had a similar degree of weight loss but experienced larger reductions in HF-related symptoms and physical limitations with semaglutide than those with lower NT-proBNP.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38819334/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38819334</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.022>10.1016/j.jacc.2024.04.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38819334</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Melanie J Davies</dc:creator>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Thomas Jon Jensen</dc:creator>
<dc:creator>Mette Nygaard Einfeldt</dc:creator>
<dc:creator>Karoline Liisberg</dc:creator>
<dc:creator>Eduardo Perna</dc:creator>
<dc:creator>Kavita Sharma</dc:creator>
<dc:creator>Justin A Ezekowitz</dc:creator>
<dc:creator>Michael Fu</dc:creator>
<dc:creator>Vojtěch Melenovský</dc:creator>
<dc:creator>Hiroshi Ito</dc:creator>
<dc:creator>Małgorzata Lelonek</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>STEP-HFpEF Trial Committees and Investigators</dc:creator>
<dc:date>2024-05-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program</dc:title>
<dc:identifier>pmid:38819334</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.022</dc:identifier>
</item>
<item>
<title>An initial invasive strategy in older patients with non-ST elevation acute coronary syndromes: it is never too late</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38819081/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 31:ehae255. doi: 10.1093/eurheartj/ehae255. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38819081/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38819081</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae255>10.1093/eurheartj/ehae255</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38819081</guid>
<pubDate>Fri, 31 May 2024 06:00:00 -0400</pubDate>
<dc:creator>J J Coughlan</dc:creator>
<dc:creator>Rory Durand</dc:creator>
<dc:creator>Robert A Byrne</dc:creator>
<dc:date>2024-05-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>An initial invasive strategy in older patients with non-ST elevation acute coronary syndromes: it is never too late</dc:title>
<dc:identifier>pmid:38819081</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae255</dc:identifier>
</item>
<item>
<title>Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38816507/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>Atrial fibrillation (AF) is a continually growing health-care burden that often presents together with metabolic disorders, including diabetes mellitus and obesity. Current treatments often fall short of preventing AF and its adverse outcomes. Accumulating evidence suggests that metabolic disturbances can promote the development of AF through structural and electrophysiological remodelling, but the underlying mechanisms that predispose an individual to AF are aetiology-dependent, thus...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 May 30. doi: 10.1038/s41569-024-01038-6. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation (AF) is a continually growing health-care burden that often presents together with metabolic disorders, including diabetes mellitus and obesity. Current treatments often fall short of preventing AF and its adverse outcomes. Accumulating evidence suggests that metabolic disturbances can promote the development of AF through structural and electrophysiological remodelling, but the underlying mechanisms that predispose an individual to AF are aetiology-dependent, thus emphasizing the need for tailored therapeutic strategies to treat AF that target an individual's metabolic profile. AF itself can induce changes in glucose, lipid and ketone metabolism, mitochondrial function and myofibrillar energetics (as part of a process referred to as 'metabolic remodelling'), which can all contribute to atrial dysfunction. In this Review, we discuss our current understanding of AF in the setting of metabolic disorders, as well as changes in atrial metabolism that are relevant to the development of AF. We also describe the potential of available and emerging treatment strategies to target metabolic remodelling in the setting of AF and highlight key questions and challenges that need to be addressed to improve outcomes in these patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38816507/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38816507</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01038-6>10.1038/s41569-024-01038-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38816507</guid>
<pubDate>Thu, 30 May 2024 06:00:00 -0400</pubDate>
<dc:creator>David Bode</dc:creator>
<dc:creator>Julius Ryan D Pronto</dc:creator>
<dc:creator>Gabriele G Schiattarella</dc:creator>
<dc:creator>Niels Voigt</dc:creator>
<dc:date>2024-05-30</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications</dc:title>
<dc:identifier>pmid:38816507</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01038-6</dc:identifier>
</item>
<item>
<title>Hypothalamic neurons that mirror aggression</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38815581/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 29:S0092-8674(24)00590-7. doi: 10.1016/j.cell.2024.05.046. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38815581/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38815581</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.046>10.1016/j.cell.2024.05.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38815581</guid>
<pubDate>Thu, 30 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Taehong Yang</dc:creator>
<dc:creator>Daniel W Bayless</dc:creator>
<dc:creator>Yichao Wei</dc:creator>
<dc:creator>Dan Landayan</dc:creator>
<dc:creator>Ivo M Marcelo</dc:creator>
<dc:creator>Yangpeng Wang</dc:creator>
<dc:creator>Laura A DeNardo</dc:creator>
<dc:creator>Liqun Luo</dc:creator>
<dc:creator>Shaul Druckmann</dc:creator>
<dc:creator>Nirao M Shah</dc:creator>
<dc:date>2024-05-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Hypothalamic neurons that mirror aggression</dc:title>
<dc:identifier>pmid:38815581</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.046</dc:identifier>
</item>
<item>
<title>RNA quality control factors nucleate Clr4/SUV39H and trigger constitutive heterochromatin assembly</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38815580/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>In eukaryotes, the Suv39 family of proteins tri-methylate lysine 9 of histone H3 (H3K9me) to form constitutive heterochromatin. However, how Suv39 proteins are nucleated at heterochromatin is not fully described. In the fission yeast, current models posit that Argonaute1-associated small RNAs (sRNAs) nucleate the sole H3K9 methyltransferase, Clr4/SUV39H, to centromeres. Here, we show that in the absence of all sRNAs and H3K9me, the Mtl1 and Red1 core (MTREC)/PAXT complex nucleates Clr4/SUV39H at...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 21:S0092-8674(24)00468-9. doi: 10.1016/j.cell.2024.04.042. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In eukaryotes, the Suv39 family of proteins tri-methylate lysine 9 of histone H3 (H3K9me) to form constitutive heterochromatin. However, how Suv39 proteins are nucleated at heterochromatin is not fully described. In the fission yeast, current models posit that Argonaute1-associated small RNAs (sRNAs) nucleate the sole H3K9 methyltransferase, Clr4/SUV39H, to centromeres. Here, we show that in the absence of all sRNAs and H3K9me, the Mtl1 and Red1 core (MTREC)/PAXT complex nucleates Clr4/SUV39H at a heterochromatic long noncoding RNA (lncRNA) at which the two H3K9 deacetylases, Sir2 and Clr3, also accumulate by distinct mechanisms. Iterative cycles of H3K9 deacetylation and methylation spread Clr4/SUV39H from the nucleation center in an sRNA-independent manner, generating a basal H3K9me state. This is acted upon by the RNAi machinery to augment and amplify the Clr4/H3K9me signal at centromeres to establish heterochromatin. Overall, our data reveal that lncRNAs and RNA quality control factors can nucleate heterochromatin and function as epigenetic silencers in eukaryotes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38815580/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38815580</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.042>10.1016/j.cell.2024.04.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38815580</guid>
<pubDate>Thu, 30 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Jasbeer S Khanduja</dc:creator>
<dc:creator>Richard I Joh</dc:creator>
<dc:creator>Monica M Perez</dc:creator>
<dc:creator>Joao A Paulo</dc:creator>
<dc:creator>Christina M Palmieri</dc:creator>
<dc:creator>Jingyu Zhang</dc:creator>
<dc:creator>Alex O D Gulka</dc:creator>
<dc:creator>Willhelm Haas</dc:creator>
<dc:creator>Steven P Gygi</dc:creator>
<dc:creator>Mo Motamedi</dc:creator>
<dc:date>2024-05-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>RNA quality control factors nucleate Clr4/SUV39H and trigger constitutive heterochromatin assembly</dc:title>
<dc:identifier>pmid:38815580</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.042</dc:identifier>
</item>
<item>
<title>Neutrophil Cathepsin G and Thrombosis in COVID-19</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38813720/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 30. doi: 10.1161/CIRCRESAHA.124.324649. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38813720/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38813720</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324649>10.1161/CIRCRESAHA.124.324649</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38813720</guid>
<pubDate>Thu, 30 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Francesco Violi</dc:creator>
<dc:creator>Simona Bartimoccia</dc:creator>
<dc:creator>Roberto Cangemi</dc:creator>
<dc:creator>Cristina Nocella</dc:creator>
<dc:creator>Alessandra D'Amico</dc:creator>
<dc:creator>Alessandra Oliva</dc:creator>
<dc:creator>Mario Venditti</dc:creator>
<dc:creator>Francesco Pugliese</dc:creator>
<dc:creator>Claudio Maria Mastroianni</dc:creator>
<dc:creator>Lorenzo Ridola</dc:creator>
<dc:creator>Miriam Lichtner</dc:creator>
<dc:creator>Vincenzo Cardinale</dc:creator>
<dc:creator>Domenico Alvaro</dc:creator>
<dc:creator>Vittoria Cammisotto</dc:creator>
<dc:creator>Valentina Castellani</dc:creator>
<dc:creator>Pasquale Pignatelli</dc:creator>
<dc:creator>Roberto Carnevale</dc:creator>
<dc:date>2024-05-30</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Neutrophil Cathepsin G and Thrombosis in COVID-19</dc:title>
<dc:identifier>pmid:38813720</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324649</dc:identifier>
</item>
<item>
<title>Internalized β2-Adrenergic Receptors Oppose PLC-Dependent Hypertrophic Signaling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38813686/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This reveals a mechanism for β2-AR antagonism of the phospholipase Cε pathway that may contribute to the known protective effects of β2-AR signaling on the development of heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 30. doi: 10.1161/CIRCRESAHA.123.323201. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Chronically elevated neurohumoral drive, and particularly elevated adrenergic tone leading to β-adrenergic receptor (β-AR) overstimulation in cardiac myocytes, is a key mechanism involved in the progression of heart failure. β1-AR (β1-adrenergic receptor) and β2-ARs (β2-adrenergic receptor) are the 2 major subtypes of β-ARs present in the human heart; however, they elicit different or even opposite effects on cardiac function and hypertrophy. For example, chronic activation of β1-ARs drives detrimental cardiac remodeling while β2-AR signaling is protective. The underlying molecular mechanisms for cardiac protection through β2-ARs remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: β2-AR signaling mechanisms were studied in isolated neonatal rat ventricular myocytes and adult mouse ventricular myocytes using live cell imaging and Western blotting methods. Isolated myocytes and mice were used to examine the roles of these signaling methods in the regulation of cardiac hypertrophy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Here, we show that β2-AR activation protects against hypertrophy through inhibition of phospholipaseCε signaling at the Golgi apparatus. The mechanism for β2-AR-mediated phospholipase C inhibition requires internalization of β2-AR, activation of Gi and Gβγ subunit signaling at endosome and ERK (extracellular regulated kinase) activation. This pathway inhibits both angiotensin II and Golgi-β1-AR-mediated stimulation of phosphoinositide hydrolysis at the Golgi apparatus ultimately resulting in decreased PKD (protein kinase D) and histone deacetylase 5 phosphorylation and protection against cardiac hypertrophy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This reveals a mechanism for β2-AR antagonism of the phospholipase Cε pathway that may contribute to the known protective effects of β2-AR signaling on the development of heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38813686/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38813686</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323201>10.1161/CIRCRESAHA.123.323201</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38813686</guid>
<pubDate>Thu, 30 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Wenhui Wei</dc:creator>
<dc:creator>Alan V Smrcka</dc:creator>
<dc:date>2024-05-30</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Internalized β2-Adrenergic Receptors Oppose PLC-Dependent Hypertrophic Signaling</dc:title>
<dc:identifier>pmid:38813686</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323201</dc:identifier>
</item>
<item>
<title>Fostering Psychological Safety and Supporting Mental Health Among Cardiovascular Health Care Workers: A Science Advisory From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38813685/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>The psychological safety of health care workers is an important but often overlooked aspect of the rising rates of burnout and workforce shortages. In addition, mental health conditions are prevalent among health care workers, but the associated stigma is a significant barrier to accessing adequate care. More efforts are therefore needed to foster health care work environments that are safe and supportive of self-care. The purpose of this brief document is to promote a culture of psychological...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 30. doi: 10.1161/CIR.0000000000001259. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The psychological safety of health care workers is an important but often overlooked aspect of the rising rates of burnout and workforce shortages. In addition, mental health conditions are prevalent among health care workers, but the associated stigma is a significant barrier to accessing adequate care. More efforts are therefore needed to foster health care work environments that are safe and supportive of self-care. The purpose of this brief document is to promote a culture of psychological safety in health care organizations. We review ways in which organizations can create a psychologically safe workplace, the benefits of a psychologically safe workplace, and strategies to promote mental health and reduce suicide risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38813685/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38813685</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001259>10.1161/CIR.0000000000001259</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38813685</guid>
<pubDate>Thu, 30 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Laxmi S Mehta</dc:creator>
<dc:creator>Keith Churchwell</dc:creator>
<dc:creator>Dawn Coleman</dc:creator>
<dc:creator>Judy Davidson</dc:creator>
<dc:creator>Karen Furie</dc:creator>
<dc:creator>Nkechinyere N Ijioma</dc:creator>
<dc:creator>Jason N Katz</dc:creator>
<dc:creator>Christine Moutier</dc:creator>
<dc:creator>Jessica Y Rove</dc:creator>
<dc:creator>Richard Summers</dc:creator>
<dc:creator>Alyssa Vela</dc:creator>
<dc:creator>Tait Shanafelt</dc:creator>
<dc:creator>American Heart Association Leadership Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Council on Quality of Care and Outcomes Research</dc:creator>
<dc:date>2024-05-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Fostering Psychological Safety and Supporting Mental Health Among Cardiovascular Health Care Workers: A Science Advisory From the American Heart Association</dc:title>
<dc:identifier>pmid:38813685</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001259</dc:identifier>
</item>
<item>
<title>A distinct platelet differentiation pathway is involved in age-related thrombocytosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38811855/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 May 29. doi: 10.1038/s41569-024-01043-9. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38811855/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38811855</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01043-9>10.1038/s41569-024-01043-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38811855</guid>
<pubDate>Wed, 29 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2024-05-29</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>A distinct platelet differentiation pathway is involved in age-related thrombocytosis</dc:title>
<dc:identifier>pmid:38811855</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01043-9</dc:identifier>
</item>
<item>
<title>Reply: Initial Medical Therapy for Stable Coronary Artery Disease: Until Death Do Us Part</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38811100/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 4;83(22):e219. doi: 10.1016/j.jacc.2024.03.418.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38811100/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38811100</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.418>10.1016/j.jacc.2024.03.418</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38811100</guid>
<pubDate>Wed, 29 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Bjorn Redfors</dc:creator>
<dc:creator>Mario F L Gaudino</dc:creator>
<dc:date>2024-05-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Initial Medical Therapy for Stable Coronary Artery Disease: Until Death Do Us Part</dc:title>
<dc:identifier>pmid:38811100</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.418</dc:identifier>
</item>
<item>
<title>Initial Medical Therapy for Stable Coronary Artery Disease: Until Death Do Us Part</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38811099/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 4;83(22):e217. doi: 10.1016/j.jacc.2024.02.057.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38811099/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38811099</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.057>10.1016/j.jacc.2024.02.057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38811099</guid>
<pubDate>Wed, 29 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Roberto Muniz Ferreira</dc:creator>
<dc:creator>Lúcia Helena Alvares Salis</dc:creator>
<dc:creator>Nelson Albuquerque de Souza E Silva</dc:creator>
<dc:date>2024-05-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Initial Medical Therapy for Stable Coronary Artery Disease: Until Death Do Us Part</dc:title>
<dc:identifier>pmid:38811099</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.057</dc:identifier>
</item>
<item>
<title>Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38811098/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>Arrhythmias frequently accompany heart failure and left ventricular dysfunction. Tachycardias, atrial fibrillation, and premature ventricular contractions can induce a reversible form of dilated cardiomyopathy (CM) known as arrhythmia-induced CM (AiCM). The intriguing question is why certain individuals are more susceptible to AiCM, despite similar arrhythmia burdens. The primary challenge is determining the extent of arrhythmias' contribution to left ventricular systolic dysfunction. AiCM...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 4;83(22):2214-2232. doi: 10.1016/j.jacc.2024.03.416.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Arrhythmias frequently accompany heart failure and left ventricular dysfunction. Tachycardias, atrial fibrillation, and premature ventricular contractions can induce a reversible form of dilated cardiomyopathy (CM) known as arrhythmia-induced CM (AiCM). The intriguing question is why certain individuals are more susceptible to AiCM, despite similar arrhythmia burdens. The primary challenge is determining the extent of arrhythmias' contribution to left ventricular systolic dysfunction. AiCM should be considered in patients with a mean heart rate of >;100 beats/min, atrial fibrillation, or a PVC burden of >;10%. Confirmation of AiCM occurs when CM reverses upon eliminating the responsible arrhythmia. Therapy choice depends on the specific arrhythmia, patient comorbidities, and preferences. After left ventricular function is restored, ongoing follow-up is essential if an abnormal myocardial substrate persists. Accurate diagnosis and treatment of AiCM have the potential to enhance patients' quality of life, improve clinical outcomes, and reduce hospital admissions and overall health care costs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38811098/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38811098</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.416>10.1016/j.jacc.2024.03.416</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38811098</guid>
<pubDate>Wed, 29 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Pouria Shoureshi</dc:creator>
<dc:creator>Alex Y Tan</dc:creator>
<dc:creator>Jayanthi Koneru</dc:creator>
<dc:creator>Kenneth A Ellenbogen</dc:creator>
<dc:creator>Karoly Kaszala</dc:creator>
<dc:creator>Jose F Huizar</dc:creator>
<dc:date>2024-05-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38811098</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.416</dc:identifier>
</item>
<item>
<title>Reperfusion Injury in Patients With Acute Myocardial Infarction: JACC Scientific Statement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38811097/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>Despite impressive improvements in the care of patients with ST-segment elevation myocardial infarction, mortality remains high. Reperfusion is necessary for myocardial salvage, but the abrupt return of flow sets off a cascade of injurious processes that can lead to further necrosis. This has been termed myocardial ischemia-reperfusion injury and is the subject of this review. The pathologic and molecular bases for myocardial ischemia-reperfusion injury are increasingly understood and include...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 4;83(22):2196-2213. doi: 10.1016/j.jacc.2024.02.056.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite impressive improvements in the care of patients with ST-segment elevation myocardial infarction, mortality remains high. Reperfusion is necessary for myocardial salvage, but the abrupt return of flow sets off a cascade of injurious processes that can lead to further necrosis. This has been termed myocardial ischemia-reperfusion injury and is the subject of this review. The pathologic and molecular bases for myocardial ischemia-reperfusion injury are increasingly understood and include injury from reactive oxygen species, inflammation, calcium overload, endothelial dysfunction, and impaired microvascular flow. A variety of pharmacologic strategies have been developed that have worked well in preclinical models and some have shown promise in the clinical setting. In addition, there are newer mechanical approaches including mechanical unloading of the heart prior to reperfusion that are in current clinical trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38811097/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38811097</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.056>10.1016/j.jacc.2024.02.056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38811097</guid>
<pubDate>Wed, 29 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Frederick G P Welt</dc:creator>
<dc:creator>Wayne Batchelor</dc:creator>
<dc:creator>J Richard Spears</dc:creator>
<dc:creator>Claudia Penna</dc:creator>
<dc:creator>Pasquale Pagliaro</dc:creator>
<dc:creator>Borja Ibanez</dc:creator>
<dc:creator>Stavros G Drakos</dc:creator>
<dc:creator>George Dangas</dc:creator>
<dc:creator>Navin K Kapur</dc:creator>
<dc:date>2024-05-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reperfusion Injury in Patients With Acute Myocardial Infarction: JACC Scientific Statement</dc:title>
<dc:identifier>pmid:38811097</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.056</dc:identifier>
</item>
<item>
<title>Transcatheter Superior Sinus Venosus Defect Closure: Experience Increases Patient Eligibility</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38811096/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 4;83(22):2193-2195. doi: 10.1016/j.jacc.2024.04.017.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38811096/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38811096</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.017>10.1016/j.jacc.2024.04.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38811096</guid>
<pubDate>Wed, 29 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Ryan Callahan</dc:creator>
<dc:creator>Matthew J Gillespie</dc:creator>
<dc:date>2024-05-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Superior Sinus Venosus Defect Closure: Experience Increases Patient Eligibility</dc:title>
<dc:identifier>pmid:38811096</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.017</dc:identifier>
</item>
<item>
<title>Transcatheter Covered Stent Exclusion of Superior Sinus Venosus Defects</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38811095/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Procedural success was 97%. Recent modifications increased patient inclusions, decreased complications, and simplified the intervention.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 4;83(22):2179-2192. doi: 10.1016/j.jacc.2024.03.417.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Transcatheter correction of sinus venosus defects (SVDs) using balloon-mounted covered stents provides an attractive surgical alternative. Surgery may be complicated by superior vena caval or right upper pulmonary vein (RUPV) stenosis, sinus nodal dysfunction, and residual additional pulmonary veins.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: Being a new intervention, technical modifications would simplify the procedure, improve universal applicability, and reduce or tackle complications.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients were included if balloon interrogation of cavoatrial junction confirmed closure of SVD and redirected RUPV to the left atrium. A single-center experience was analyzed to summarize the procedural modifications over 8 years. Transesophageal echocardiogram (TEE) on follow-up was done to identify residual shunt, RUPV flows, and stent thrombosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 100 patients including 9 children with a median age of 35 years (range, 4-69 years) underwent SVD closure after balloon interrogation. Among 57 patients balloon interrogated in the first 5 years, 70% underwent transcatheter closure, with 2 failures. RUPV occlusion caused the exclusions. Inclusions improved to 94% among the subsequent 65 balloon interrogations when RUPV protection was implemented, with 1 failure. Stent embolization caused the 3 failures warranting surgery. Recent modifications included limited transesophageal echocardiogram without anesthesia, avoiding venovenous circuit, interrogation with semicompliant balloons, trans-septal RUPV protection, overlapping stents to permit additional vein drainage to superior vena cava and tackle embolizations. There were no deaths. Minor complications included stent embolizations stabilized in catheterization laboratory in 2 patients, left innominate vein jailing in 2 patients, insignificant residual flows, and nonocclusive asymptomatic stent thrombosis in 4 patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Procedural success was 97%. Recent modifications increased patient inclusions, decreased complications, and simplified the intervention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38811095/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38811095</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.417>10.1016/j.jacc.2024.03.417</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38811095</guid>
<pubDate>Wed, 29 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Pramod Sagar</dc:creator>
<dc:creator>Kothandam Sivakumar</dc:creator>
<dc:creator>Puthiyedath Thejaswi</dc:creator>
<dc:creator>Monica Rajendran</dc:creator>
<dc:date>2024-05-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Covered Stent Exclusion of Superior Sinus Venosus Defects</dc:title>
<dc:identifier>pmid:38811095</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.417</dc:identifier>
</item>
<item>
<title>Enhancing HDL Function to Prevent Atherothrombosis: Is it Time to Efflux the HDL Hypothesis?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38811094/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 4;83(22):2175-2178. doi: 10.1016/j.jacc.2024.04.015.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38811094/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38811094</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.015>10.1016/j.jacc.2024.04.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38811094</guid>
<pubDate>Wed, 29 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Aloke V Finn</dc:creator>
<dc:date>2024-05-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Enhancing HDL Function to Prevent Atherothrombosis: Is it Time to Efflux the HDL Hypothesis?</dc:title>
<dc:identifier>pmid:38811094</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.015</dc:identifier>
</item>
<item>
<title>Revisiting a "Paradigm" in Cardiovascular and Kidney Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38811093/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240531141138&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 4;83(22):2160-2162. doi: 10.1016/j.jacc.2024.04.018.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38811093/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240531141138&v=2.18.0.post9+e462414">38811093</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.018>10.1016/j.jacc.2024.04.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38811093</guid>
<pubDate>Wed, 29 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Glenn M Chertow</dc:creator>
<dc:date>2024-05-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Revisiting a "Paradigm" in Cardiovascular and Kidney Disease</dc:title>
<dc:identifier>pmid:38811093</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.018</dc:identifier>
</item>





























</channel>
</rss>